NASDAQ$XBIT
XBiotech Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
XBiotech reported a net loss of $5.5 million for the first quarter of 2026.
XBiotech Inc. continued its focus on clinical development of True Human monoclonal antibodies targeting IL-1a. The company recorded operating expenses of $6.3 million, primarily in research and development, resulting in a net loss of $5.5 million or $0.18 per share. Cash and cash equivalents declined to $115.5 million at quarter end.
- Net loss narrowed to $5.5 million from $10.9 million in Q1 2025.
- R&D expenses decreased 55% year-over-year to $5.2 million.
- Cash position remained strong at $115.5 million with no debt.
- Company maintains pipeline progress in oncology, rheumatology and neurology indications.
Headline financials
Revenue & EPS history
XBiotech · Revenue · Quarterly
$0
Forward guidance
No explicit financial guidance provided for 2026.
Tailwinds
- Sufficient cash runway through at least 12 months.
- Ongoing clinical studies in multiple therapeutic areas.
Headwinds
- Continued net losses expected as pipeline advances.
- No product revenue anticipated in 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
+0.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
19 / 43 earnings
Positive
+13.5%
Q1 2016
Best reaction
-11.2%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.6% | — | — | |
| Q3 2025 | -5.8% | -16.0% | -18.4% | |
| Q2 2025 | +5.7% | +7.7% | -7.4% | |
| Q1 2025 | -1.7% | -3.4% | -5.4% | |
| Q4 2024 | +4.5% | -4.8% | -7.1% | |
| Q3 2024 | -1.7% | -5.9% | -2.0% | |
| Q2 2024 | -2.4% | -7.9% | -1.8% | |
| Q4 2023 | +4.2% | +12.6% | +45.4% | |
| Q3 2023 | -0.4% | -3.7% | +5.4% | |
| Q2 2023 | -3.0% | -4.3% | -5.1% | |
| Q1 2023 | +2.4% | +1.8% | +66.2% | |
| Q4 2022 | +4.9% | +1.5% | +9.2% | |
| Q3 2022 | -1.4% | +1.1% | -9.9% | |
| Q2 2022 | -1.6% | -1.4% | -20.0% | |
| Q1 2022 | -5.0% | -9.6% | -7.5% | |
| Q4 2021 | +2.0% | +6.8% | -7.1% | |
| Q3 2021 | -4.2% | -7.3% | -25.2% | |
| Q2 2021 | +1.4% | -1.3% | -3.0% | |
| Q1 2021 | +2.8% | +0.1% | +0.3% | |
| Q4 2020 | -3.1% | -2.5% | -14.9% | |
| Q3 2020 | +5.1% | +5.3% | -1.1% | |
| Q2 2020 | +6.8% | +14.4% | +29.6% | |
| Q1 2020 | +0.9% | -9.3% | -10.0% | |
| Q4 2019 | -1.2% | -7.8% | +32.2% | |
| Q3 2019 | +2.9% | +12.6% | +77.6% | |
| Q2 2019 | -0.7% | +7.1% | +22.0% | |
| Q1 2019 | +3.3% | -2.6% | -17.9% | |
| Q4 2018 | -4.6% | +10.3% | -5.0% | |
| Q3 2018 | -0.5% | +3.7% | +17.3% | |
| Q2 2018 | +3.5% | +9.7% | -10.7% | |
| Q1 2018 | +0.0% | +3.3% | +1.9% | |
| Q4 2017 | +6.7% | +5.1% | +9.4% | |
| Q3 2017 | +2.0% | -0.2% | +16.5% | |
| Q2 2017 | -5.0% | +4.1% | +14.4% | |
| Q1 2017 | -11.2% | -10.7% | -68.2% | |
| Q4 2016 | +6.5% | +10.0% | +3.2% | |
| Q3 2016 | +10.3% | +9.1% | -6.7% | |
| Q2 2016 | -5.6% | -2.2% | -9.7% | |
| Q1 2016 | +13.5% | — | — | |
| Q4 2015 | -6.1% | — | — | |
| Q3 2015 | -7.0% | — | — | |
| Q2 2015 | -1.0% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro